The new Amass app is live. Ask in plain language, check every claim. Try it free

Skills & PromptsResmetirom evidence snapshot

Prompt

Resmetirom evidence snapshot

Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.

See the prompt

New to Amass? Connect Amass to Claude first

2MAESTRO trials
2024FDA approval
You getpdf1 file
Promptresearchclaude

The prompt

Paste this into Claude

Drug assetresmetirom
prompt
DRUG ASSET: resmetirom

You have the Amass MCP connected (TrialCore + BiomedCore). Produce a one-page EVIDENCE SNAPSHOT
PDF for this asset — every figure traceable to an Amass record.

1. STATUS + PIVOTAL TRIALS. Call search_amass_trialcore_records with:
     query = the DRUG ASSET + indication terms, phase = "PHASE3"
   Keep the registrational trials; capture NCT, acronym, sponsor, status and enrollment verbatim.

2. EFFICACY. Call search_amass_biomedcore_records with:
     query = the DRUG ASSET + indication terms, minJournalQualityJufo = 2, isRetracted = false
   Pull 2–3 grounded findings; quote every number (%, mg, P, fibrosis stage) VERBATIM from the
   abstract. Tag each with PMID, journal, JuFo tier, citationCount.

3. CROSS-CORE PROVENANCE. For the pivotal trial, call get_amass_trialcore_record and read its
   referencesBiomedCore links — show NCT ↔ PMID, the publication↔trial edge.

4. Lay sections 1–3 out as a single-page .pdf snapshot: a regulatory-status callout, the trial
   table, the grounded findings, and the provenance line. Close with a scope note — figures are
   verbatim from Amass records as of <date>; this is an evidence digest, not regulatory advice.

Why not just ask the model?

Ask a plain model for "a one-pager on resmetirom" and you get a confident page of unverifiable numbers — a fat-fraction here, an approval date there, a trial ID that won't resolve.

  • Plain model: invents the hepatic-fat reduction, guesses the approval date, cites an NCT that doesn't resolve.
  • Amass: −34.9% / −38.6% hepatic fat (PMID 37845512) · FDA accelerated approval, March 2024, F2–F3 fibrosis (PMID 38771485) · 56.6% vs 33.8% MASH resolution with weight loss (PMID 41127972) · NCT03900429 → PMID 41895606 — each figure copied from the record, not recalled.

Honest scope

A snapshot, not a dossier: two pivotal trials and a few grounded figures chosen to fit one page, not a complete program or a meta-analysis. MAESTRO-NASH is still ACTIVE_NOT_RECRUITING (long-term outcomes ongoing); every figure is verbatim from the cited abstract as of the run date and traceable by the PMIDs and Amass IDs on the page. An evidence digest, not regulatory advice.

More from the library

Keep exploring

xlsx
14trials watched
Short nameSource idRegistryCopy of
Acute, 50/75 mg vs placeboNCT04072354ClinicalTrials.gov
↳ EUCTR2019-000470-36-BGEU CTRNCT04072354
Acute, 75/100 mg vs placeboNCT04092686ClinicalTrials.gov
competitive-intelligenceSkill

Watchlist Monitor

Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.

pdf+1
196trials in scope
Landscape Monitor — page 1
competitive-intelligenceSkill

Landscape Monitor

Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.

csv
12targets scored
kinasekinase_family_chembl_leafsmall_molecule_tractabilityprotac_tractability
PLK1Other protein kinase PLK familyAdvanced Clinicalpredictive-only
WEE1Other protein kinase WEE familyAdvanced Clinicalpredictive-only
CDK1CMGC protein kinase CDK5 subfamilyAdvanced Clinicalpredictive-only
researchSkill

Target prioritization matrix

A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.

Run it yourself

Connect Amass to Claude and paste the prompt.

The connector takes about a minute to add, then this workflow runs on your own inputs.

Data
No training on your data
Hosting
EU-hosted, enterprise
Isolation
Tenant-isolated by architecture
Certification
ISO 27001, SOC 2, NIS2: in motion